HashiCorp (HCP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Citigroup has recently resumed HashiCorp Inc (HCP) stock to Neutral rating, as announced on September 3, 2024, according to Finviz. Earlier, on April 24, 2024, BTIG Research had reduced the stock from ...

Hyderabad:Hyderabad city police will conduct a public auction to dispose of 1,087 abandoned / unclaimed vehicles of various ...

Check the time stamp on this data. Updated AI-Generated Signals for Hashicorp Inc. (HCP) available here: HCP.

The US Food and Drug Administration (FDA) has announced a final rule expanding the approval pathway for nonprescription drug ...

On Thursday, HashiCorp Inc (HCP) stock saw a decline, ending the day at $34.17 which represents a decrease of $-0.04 or -0.12% from the prior close of $34.21. The stock opened at $34.24 and touched a ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Headquartered in Irvine, CA, HCP, Inc. is a real estate investment trust (REIT) in the United States that acquires, develops, manages, sells and leases a diverse portfolio of healthcare real ...

HashiCorp, Inc. (NASDAQ:HCP – Get Free Report)’s share price reached a new 52-week high during trading on Friday . The stock traded as high as $34.39 and last traded at $34.38, with a volume of ...

Shares of HashiCorp, Inc. (NASDAQ:HCP – Get Free Report) have received a consensus recommendation of “Hold” from the fourteen research firms that are currently covering the company, Marketbeat Ratings ...

The U.S. Food and Drug Administration (FDA) recently announced final guidance for firms in the medical device and product industry ...